Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$8.60M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$13.74M

FY 2025 · Annual

+140.6% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(13.45M)(37.57M)(21.27M)(10.88M)(11.92M)
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
Deferred Income Tax5.34M0000
Stock-Based Compensation1.9M0477.5K1.1M1.22M
Change in Working Capital(2.98M)(550.34K)1.73M(125.26K)(1.46M)
Accounts Receivables21.79K(8.08K)(30.9K)(234.74K)(7.35K)
Inventory(422.02K)0000
Accounts Payables(1.58M)(35.07K)1.32M(149.94K)(381.01K)
Other Working Capital(1M)(507.19K)437.31K259.42K(1.07M)
Other Non-Cash Items4.26M33.25M10.79M2.21M2.34M
Operating Cash Flow(4.49M)(3.88M)(7.24M)(6.65M)(8.6M)
Capital Expenditures(1.75M)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.75M)0000
Debt Repayment(1.62M)(2.42M)(575K)1.2M771.25K
Common Stock Issued10.14M3.27M5.29M100K12.97M
Common Stock Repurchased(247.17K)0000
Dividends Paid00000
Other Financing Activities(50.9K)4.63M200K500K0
Financing Cash Flow8.22M5.49M4.92M5.71M13.74M
Effect of Forex Changes00000
Net Change in Cash1.98M1.61M(2.32M)(936.25K)5.14M
Free Cash Flow(6.24M)(3.88M)(7.24M)(6.65M)(8.6M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$11.9M
+ D&A$1.2M
+ Stock-Based Comp$1.2M
+ Deferred Tax$0
- Working Capital-$1.5M
+ Other Non-Cash$2.3M
= Operating Cash Flow-$8.6M
- Capex$0
= Free Cash Flow-$8.6M

Analysis

FY2025 free cash flow is -$8.6M. FCF conversion is 72.2% of net income. Operating cash flow was -$8.6M, with capex of $0. The largest bridge item is Other Non-Cash at $2.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
424B3424B3 filingJun 18, 2026
EFFECTEFFECT filingJun 16, 2026
POS AMPOS AM filingJun 16, 2026
S-1S-1 filingJun 9, 2026
4Statement of changes in beneficial ownershipJun 8, 2026

Does COEP generate free cash flow?

Coeptis Therapeutics, Inc. (COEP) generated -$8.60M of free cash flow in fiscal 2025.

How much operating cash flow does COEP produce?

Operating cash flow was -$8.60M, before capital expenditures of $0.00.